Cerebrospinal Fluid Myeloperoxidase Is Associated With Putamen Volume Beyond Neurofilament Light in Huntington’s Disease
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
The primary neuroanatomical site of Huntington’s disease (HD) pathology resides in the striatum and its atrophy identifies important disease progression from HD-ISS Stage 0 to Stage 1. Immune-associated proteins may capture variation in HD that is incompletely represented by markers of neuroaxonal injury.
Objectives
To determine whether cerebrospinal-fluid myeloperoxidase contributes information about striatal volume loss beyond genetic disease burden and neurofilament light.
Methods
Cross-sectional data from 88 persons with HD were analyzed. Cerebrospinal-fluid myeloperoxidase and neurofilament light were measured with a nucleic acid-linked immunosandwich assay. Normalized putamen volume was derived from structural magnetic resonance imaging. Linear regression adjusted for genetic disease burden and sex.
Results
Higher neurofilament light was associated with smaller normalized putamen volume (standardized β = −0.322, (P=.0066)). Higher myeloperoxidase was associated with larger normalized putamen volume after adjustment for genetic disease burden, sex, and neurofilament light (standardized β = 0.183, (P=.0386)). Adding myeloperoxidase increased explained variance in striatal loss.
Conclusions
Cerebrospinal fluid myeloperoxidase contributed modest incremental information about striatal volume in this cross-sectional sample. Independent longitudinal studies are needed to determine its biological source, temporal behavior, and potential biomarker value. Findings advance efforts to characterize multicomponent biological markers of HD.
